Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AG
Agenus Inc.
AGEN
Mkt Cap
$272.6M
Volume
970.13K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AG
AGEN
AG
Agenus Inc.
AGEN
News
·
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type
Mkt Cap
$301.7M
Volume
970.13K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type
A comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations and bispecific antibodies.
GlobeNewswire Inc. · Feb 18, 2026
Agenus (AGEN) Q3 2024 Earnings Call Transcript
Agenus reported Q3 2024 results highlighting groundbreaking clinical progress with BOT/BAL immunotherapy in hard-to-treat cancers, particularly microsatellite-stable colorectal cancer. However, the company faces significant financial constraints with only $44.8 million in cash at quarter-end. Management is pursuing cost reductions, real estate asset monetization ($45M+ in properties), and strategic partnerships to fund Phase 3 trials and extend runway. Multiple data presentations from neoadjuvant trials are expected in early 2025.
The Motley Fool · Jan 5, 2026
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.
Benzinga · Aug 28, 2025
PD-(L)1 Inhibitors Market Set to Surge During the Forecast Period (2025–2034) as Immuno-Oncology Therapies Gain Momentum | DelveInsight
PD-(L)1 inhibitors are projected to dominate future drug sales, revolutionizing cancer care across multiple tumor types with flexible treatment approaches and promising clinical outcomes.
GlobeNewswire Inc. · Aug 18, 2025
U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034
The U.S. pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is expected to grow from $36.77 billion in 2024 to $68.57 billion by 2034, driven by increased demand for specialized pharmaceutical services, technological advancements, and growing needs in oncology and complex drug development.
GlobeNewswire Inc. · Aug 13, 2025
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Several biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.
Benzinga · Jul 29, 2025
Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030
The global market for Neoantigen Cancer Vaccines is expected to grow significantly, driven by advancements in precision oncology, next-generation sequencing, and bioinformatics. Key players in this burgeoning market include Agenus Inc., BioNTech SE, and Candel Therapeutics.
GlobeNewswire Inc. · Jun 13, 2025
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that it will present interim data from its ongoing Phase 2 study testing AgenT-797 in combination with Agenus' botensilimab and balstilimab in patients with refractory gastric cancer.
GlobeNewswire Inc. · Feb 12, 2025
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
MiNK Therapeutics presented data on a Phase 2 trial evaluating a combination of its iNKT cell therapy, Agenus' botensilimab and balstilimab, and standard chemotherapy in advanced gastroesophageal cancer patients. The novel combination demonstrated signals of tolerability and activity in this patient population.
GlobeNewswire Inc. · Jan 23, 2025
Agenus (AGEN) Q3 2024 Earnings Call Transcript
Agenus, a biotech company, reported its Q3 2024 earnings. The company's lead drug candidate, BOT/BAL, is showing promising results in treating various cancers, including microsatellite stable colorectal cancer. However, Agenus is facing financial challenges and is exploring strategic transactions and asset monetization to support the development of BOT/BAL.
The Motley Fool · Nov 12, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AG
AGEN
Agenus Inc.
Buy
Sell
Market
Limit
Soon
AGEN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any AGEN yet.
Related Tickers
Earnings